• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Former SEC Director of Corporation Finance Bill Hinman Joins &vest as Partner

    5/17/21 5:15:00 PM ET
    $VELO
    $AMRS
    $FST
    Consumer Electronics/Appliances
    Industrials
    Major Chemicals
    Industrials
    Get the next $VELO alert in real time by email

    RIDGEFIELD, Conn., May 17, 2021 /PRNewswire/ -- &vest, an investment platform founded in 2019 focused on SPACs and private investments, today announced that Bill Hinman has joined the company as Partner.

    Hinman served as Director of Corporation Finance at the U.S. Securities and Exchange Commission (SEC) from 2017 to 2020, where he was primarily responsible for overseeing regulations and processes for initial public offerings and other corporate disclosures.    During his tenure at the SEC, Mr. Hinman spearheaded nearly 50 policy and rulemaking initiatives designed to strengthen public markets as well as modernize and improve the framework for companies accessing capital markets, including addressing the large increase in SPAC offerings.

    Prior to his tenure at the SEC, Hinman was as a partner at Simpson Thacher & Bartlett LLP (where he recently returned as a senior advisor). Mr. Hinman played a leading role in the IPOs of Alibaba, Facebook, Google, eBay, Square, Agilent, Seagate and VMware, among many others, and he has represented a wide range of issuers and underwriters in capital-raising transactions and corporate acquisitions.

    At &vest, Hinman will serve as a partner advising on capital markets efforts, as well as key legal and regulatory matters.

    "Bill's professional experience is unmatched as we navigate the shifting SPAC regulatory landscape and continue to engage with companies preparing to enter the public markets," said Doug Jacob, &vest founder. "His unique blend of public and private service as well as his insight into the regulatory changes we know will come to the SPAC market provide us and the companies we combine with a significant strategic advantage.  We are thrilled he has joined our team and believe he will have a tremendous impact on all &vest stakeholders."

    &vest was founded in 2019 by Doug Jacob and Michael Lastoria as an innovative investment platform that leverages the firm's branding, operational, and financial capabilities to create unique investment opportunities across a variety of strategies. 

    Initially focused on growth and venture investments, &vest in 2020 launched FAST Acquisition Corp. (NYSE:FST), a $200M SPAC that recently announced a definitive agreement to merge with Fertitta Entertainment Inc. in a $6.6B transaction.  &vest has since launched FAST Acquisition Corp. II (NYSE:FZT) focused on consumer and hospitality targets, and Velocity Acquisition Corp. (NASDAQ:VELO) focused on digital transformation companies.  &vest's private investments include &pizza – a 50-unit fast casual pizza brand that Jacob co-founded with Lastoria in 2010, Beauty Labs – a beauty technology business that recently announced that it had agreed to be acquired by Amyris Inc. (NASDAQ:AMRS), Rumble Fitness – which recently was acquired by Xponential Fitness, and Butler Hospitality, among others. 

    Collectively, through its SPACs and private investments, &vest has raised nearly $2B of investment capital.

    "I am excited to join Doug and the &vest team," said Mr. Hinman.  "The SPAC model offers companies that are seeking to raise capital in the public markets an attractive alternative to the traditional IPO.  This is particularly the case when the SPAC sponsor offers a skill set that goes beyond access to public investors.  In the case of Doug and the &vest team, I am impressed with their track record in brand development and in wisely deploying capital.  Doug and the entire &vest team has recognized that meeting the regulatory and compliance challenges that accompany joining the public markets through a SPAC is a key to success.  I look forward to assisting &vest and its partners as we tackle these challenges and work to develop companies that thrive in the public markets."

    Prior to joining Simpson Thacher in 2000, Hinman was the managing partner of Shearman & Sterling's San Francisco and Menlo Park offices. Hinman received his B.A. from Michigan State University with honors in 1977 and his J.D. in 1980 from Cornell University Law School. He is a member of the Bar in the States of California and New York. He is also a fellow of the American Bar Foundation.

    About &vest

    &vest is a unique investment platform founded by Doug Jacob and Michael Lastoria in 2019 that leverages its branding, operational, financial and partnership capabilities in to create bespoke investment opportunities for its investors. To date, &vest has successfully launched three SPACS: FAST Acquisition Corp., FAST Acquisition Corp. II, and Velocity Acquisition Corp., as well as a series of private growth and venture investments.  &vest is headquartered in Ridgefield, Connecticut. More information can be found at https://andvest.co.

    Media Contact:

    Hiltzik Strategies

    Chris Cunningham

    [email protected]

    Cision View original content:http://www.prnewswire.com/news-releases/former-sec-director-of-corporation-finance-bill-hinman-joins-vest-as-partner-301292947.html

    SOURCE &vest

    Get the next $VELO alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $VELO
    $AMRS
    $FST

    CompanyDatePrice TargetRatingAnalyst
    Amyris Inc.
    $AMRS
    5/18/2023$3.10 → $0.65Buy → Hold
    Jefferies
    Amyris Inc.
    $AMRS
    5/10/2023$4.00 → $1.25Outperform → Market Perform
    TD Cowen
    Amyris Inc.
    $AMRS
    4/28/2023$1.50Buy
    Canaccord Genuity
    Amyris Inc.
    $AMRS
    11/10/2022Overweight → Neutral
    JP Morgan
    Amyris Inc.
    $AMRS
    11/9/2022Outperform → Perform
    Oppenheimer
    Amyris Inc.
    $AMRS
    8/10/2022$4.00 → $2.00Buy → Neutral
    ROTH Capital
    Amyris Inc.
    $AMRS
    6/24/2022Neutral
    JP Morgan
    Amyris Inc.
    $AMRS
    5/25/2022$2.50Neutral
    Piper Sandler
    More analyst ratings

    $VELO
    $AMRS
    $FST
    SEC Filings

    See more
    • SEC Form S-8 POS filed by Amyris Inc.

      S-8 POS - AMYRIS, INC. (0001365916) (Filer)

      2/9/24 9:14:56 PM ET
      $AMRS
      Major Chemicals
      Industrials
    • SEC Form S-8 POS filed by Amyris Inc.

      S-8 POS - AMYRIS, INC. (0001365916) (Filer)

      2/9/24 9:11:00 PM ET
      $AMRS
      Major Chemicals
      Industrials
    • SEC Form S-8 POS filed by Amyris Inc.

      S-8 POS - AMYRIS, INC. (0001365916) (Filer)

      2/9/24 9:12:50 PM ET
      $AMRS
      Major Chemicals
      Industrials

    $VELO
    $AMRS
    $FST
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • AVITA Medical Appoints Nicole Kelsey as Chief Legal and Compliance Officer, and Corporate Secretary

      VALENCIA, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced the appointment of Nicole Linda Kelsey as Chief Legal and Compliance Officer, and Corporate Secretary, effective July 1, 2024. Ms. Kelsey has more than two decades of executive legal experience with expertise in M&A, securities, and governance, along with a strong track record building and leading global regulatory and compliance programs. Previously, she served as Chief Legal Officer and Secretary for Amyris, Inc. (NASDAQ:AMRS) and General Counse

      7/1/24 4:05:00 PM ET
      $RCEL
      $AMRS
      Medical/Dental Instruments
      Health Care
      Major Chemicals
      Industrials
    • AMYRIS ANNOUNCES OPERATIONAL AND FINANCIAL RESTRUCTURING TO ADVANCE STRATEGIC TRANSFORMATION

      Voluntary Chapter 11 Commenced to Finalize Consensual Go-Forward Plan for Amyris' Core Business $190 Million Financing Commitment from Foris Ventures to Support Day-to-Day Operations EMERYVILLE, Calif., Aug. 9, 2023 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS) ("Amyris" or the "Company"), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, today announced that it is moving forward with an operational and financial restructuring to further advance its ongoing strategic transformation and position the Company for long-term success.

      8/9/23 9:38:00 PM ET
      $AMRS
      Major Chemicals
      Industrials
    • AMYRIS ANNOUNCES CEO TRANSITION AND GLOBAL REDUCTION IN FORCE

      EMERYVILLE, Calif., June 26, 2023 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, today announced that John Melo has resigned from his role as President & Chief Executive Officer and a member of the Board of Directors, effective immediately. The Company's Board of Directors has appointed Han Kieftenbeld as Interim Chief Executive Officer. Mr. Kieftenbeld will remain as the Company's Chief Financial Officer. The Company also announced a global reduction in force as an important step towards its previously announce

      6/26/23 9:10:00 AM ET
      $AMRS
      Major Chemicals
      Industrials

    $VELO
    $AMRS
    $FST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Amyris downgraded by Jefferies with a new price target

      Jefferies downgraded Amyris from Buy to Hold and set a new price target of $0.65 from $3.10 previously

      5/18/23 7:22:16 AM ET
      $AMRS
      Major Chemicals
      Industrials
    • Amyris downgraded by TD Cowen with a new price target

      TD Cowen downgraded Amyris from Outperform to Market Perform and set a new price target of $1.25 from $4.00 previously

      5/10/23 7:29:32 AM ET
      $AMRS
      Major Chemicals
      Industrials
    • Canaccord Genuity initiated coverage on Amyris with a new price target

      Canaccord Genuity initiated coverage of Amyris with a rating of Buy and set a new price target of $1.50

      4/28/23 7:13:42 AM ET
      $AMRS
      Major Chemicals
      Industrials

    $VELO
    $AMRS
    $FST
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider White J. Scott

      3 - AMYRIS, INC. (0001365916) (Issuer)

      9/20/23 8:09:50 PM ET
      $AMRS
      Major Chemicals
      Industrials
    • SEC Form 3 filed by new insider Gund Philip J.

      3 - AMYRIS, INC. (0001365916) (Issuer)

      8/17/23 7:35:56 PM ET
      $AMRS
      Major Chemicals
      Industrials
    • SEC Form 3 filed by new insider Reiss M. Freddie

      3 - AMYRIS, INC. (0001365916) (Issuer)

      8/17/23 7:32:49 PM ET
      $AMRS
      Major Chemicals
      Industrials

    $VELO
    $AMRS
    $FST
    Leadership Updates

    Live Leadership Updates

    See more
    • AVITA Medical Appoints Nicole Kelsey as Chief Legal and Compliance Officer, and Corporate Secretary

      VALENCIA, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced the appointment of Nicole Linda Kelsey as Chief Legal and Compliance Officer, and Corporate Secretary, effective July 1, 2024. Ms. Kelsey has more than two decades of executive legal experience with expertise in M&A, securities, and governance, along with a strong track record building and leading global regulatory and compliance programs. Previously, she served as Chief Legal Officer and Secretary for Amyris, Inc. (NASDAQ:AMRS) and General Counse

      7/1/24 4:05:00 PM ET
      $RCEL
      $AMRS
      Medical/Dental Instruments
      Health Care
      Major Chemicals
      Industrials
    • AMYRIS ANNOUNCES CEO TRANSITION AND GLOBAL REDUCTION IN FORCE

      EMERYVILLE, Calif., June 26, 2023 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, today announced that John Melo has resigned from his role as President & Chief Executive Officer and a member of the Board of Directors, effective immediately. The Company's Board of Directors has appointed Han Kieftenbeld as Interim Chief Executive Officer. Mr. Kieftenbeld will remain as the Company's Chief Financial Officer. The Company also announced a global reduction in force as an important step towards its previously announce

      6/26/23 9:10:00 AM ET
      $AMRS
      Major Chemicals
      Industrials
    • AMYRIS ANNOUNCES APPOINTMENT OF ANA DUTRA TO BOARD OF DIRECTORS

      EMERYVILLE, Calif., Jan. 27, 2022 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS) ("Amyris"), a leading synthetic biotechnology company accelerating the world to sustainable consumption through its Lab-to-MarketTM operating platform, today announced the appointment of Ms. Ana Dutra as its newest independent member of the Amyris Board of Directors, effective January 21, 2022. "We are very pleased to welcome Ana as a new, independent director to Amyris," said John Melo, President and Chief Executive Officer of Amyris. "Ana brings decades of leadership, operational depth and highly re

      1/27/22 8:00:00 AM ET
      $AMRS
      Major Chemicals
      Industrials

    $VELO
    $AMRS
    $FST
    Financials

    Live finance-specific insights

    See more
    • AMYRIS TO HOST FIRST QUARTER 2023 FINANCIAL RESULTS CONFERENCE CALL ON MAY 9

      EMERYVILLE, Calif., May 2, 2023 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, today announced that it will issue its financial results for the first quarter ended March 31, 2023, on the afternoon of Tuesday, May 9, 2023, after closing of the financial markets. The company will hold a conference call and webcast at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time), during which, John Melo, President

      5/2/23 8:00:00 AM ET
      $AMRS
      Major Chemicals
      Industrials
    • AMYRIS, INC. REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS

      Fourth quarter Consumer revenue of $52.8 million increased 64% over the prior year and was another record quarter. Core revenue of $75.8 million grew 17% over the prior yearFull year Consumer revenue of $176.9 million increased 92% and outperformed prestige beauty industry growth of 15%. Core revenue of $269.8 million grew 44% over prior yearUse of cash for operating and investing activities sequentially improved each quarter; Q4 2022 down $102 million versus Q1 2022Actions taken to simplify portfolio, streamline management structure and deliver efficienciesEMERYVILLE, Calif., March 15, 2023 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company accelerating th

      3/15/23 4:11:00 PM ET
      $AMRS
      Major Chemicals
      Industrials
    • AMYRIS TO HOST FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS CONFERENCE CALL ON MARCH 15, 2023

      EMERYVILLE, Calif., Feb. 28, 2023 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, today announced that it will issue its financial results for the fourth quarter and full year ended December 31, 2022, on the afternoon of Wednesday, March 15, 2023, after closing of the financial markets. The company will hold a conference call and webcast at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time), during wh

      2/28/23 8:00:00 AM ET
      $AMRS
      Major Chemicals
      Industrials

    $VELO
    $AMRS
    $FST
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Amyris Inc. (Amendment)

      SC 13D/A - AMYRIS, INC. (0001365916) (Subject)

      1/5/24 4:22:57 PM ET
      $AMRS
      Major Chemicals
      Industrials
    • SEC Form SC 13D/A filed by Amyris Inc. (Amendment)

      SC 13D/A - AMYRIS, INC. (0001365916) (Subject)

      12/14/23 4:34:27 PM ET
      $AMRS
      Major Chemicals
      Industrials
    • SEC Form SC 13D/A filed by Amyris Inc. (Amendment)

      SC 13D/A - AMYRIS, INC. (0001365916) (Subject)

      10/16/23 4:41:27 PM ET
      $AMRS
      Major Chemicals
      Industrials